Comparative Pharmacology
Head-to-head clinical analysis: FLURBIPROFEN versus ZIPSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLURBIPROFEN versus ZIPSOR.
FLURBIPROFEN vs ZIPSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclooxygenase (COX) inhibitor, reducing prostaglandin synthesis; nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects.
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis involved in inflammation, pain, and fever. It has no significant inhibition of COX-1 at therapeutic doses.
Oral: 50-100 mg every 6-8 hours; maximum 300 mg/day. Ophthalmic: 1 drop every 30 minutes starting 2 hours before surgery, then 1 drop every 4-6 hours for 24-48 hours post-surgery.
50 mg orally three times daily
None Documented
None Documented
Clinical Note
moderateFlurbiprofen + Gatifloxacin
"Flurbiprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateFlurbiprofen + Rosoxacin
"Flurbiprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateFlurbiprofen + Levofloxacin
"Flurbiprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateFlurbiprofen + Trovafloxacin
Terminal elimination half-life: 3-4 hours (healthy adults) in short-term use; prolonged to 6-12 hours in elderly or renal impairment.
2-4 hours (terminal); clinical context: short half-life necessitates frequent dosing for sustained relief; prolonged in hepatic impairment
Renal: 70% as conjugated metabolites (e.g., glucuronides) and <5% unchanged; biliary/fecal: 30%, with enterohepatic circulation.
Renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; remainder as glucuronide conjugates
Category D/X
Category C
NSAID
NSAID
"Flurbiprofen may increase the neuroexcitatory activities of Trovafloxacin."